VIP通过LRRK2转录调控改变Schlemm管内皮F-/G-肌动蛋白比值
本研究在大鼠体内及人脐静脉内皮细胞中探究VIP调控Schlemm管内皮细胞骨架的分子机制。结果显示VIP经Sp1核转位上调LRRK2表达,进而改变F-/G-肌动蛋白比值,该效应可被LRRK2抑制剂消除,提示Sp1-LRRK2通路是潜在青光眼治疗靶点。
要点
- VIP在体内外均上调LRRK2表达,并促进Sp1核转位。
- Sp1抑制剂可消除VIP诱导的LRRK2表达增加。
- LRRK2抑制剂可消除VIP对F-/G-肌动蛋白比值的改变。
核心结论
- VIP通过Sp1核转位上调LRRK2表达,进而改变F-/G-肌动蛋白比值,调控F-肌动蛋白结构的稳定与去稳定平衡。
- 该研究阐明VIP经Sp1-LRRK2通路调控Schlemm管内皮肌动蛋白细胞骨架的新机制,提示青光眼潜在治疗策略。
研究设计与样本
- 大鼠体内实验:应用VIP后免疫荧光检测Schlemm管周围LRRK2表达及F-/G-肌动蛋白比值。
- 人脐静脉内皮细胞体外实验:qPCR和western blotting评估VIP及Sp1/LRRK2抑制剂对Sp1和LRRK2表达的影响。
- 体外实验:免疫荧光和western blotting检测VIP及LRRK2抑制剂对F-/G-肌动蛋白比值的影响。
主要发现
- VIP在体内和体外均诱导LRRK2表达增加。
- VIP在体外促进Sp1核转位。
- Sp1抑制剂在体外消除VIP诱导的LRRK2表达增加。
- VIP改变F-/G-肌动蛋白比值,该效应在体内和体外均被LRRK2抑制剂消除。
临床怎么用
- VIP经Sp1-LRRK2通路调控Schlemm管内皮细胞骨架,为青光眼治疗提供潜在新靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A previous study reported that vasoactive intestinal peptide (VIP) can regulate the cytoskeleton of Schlemm's canal (SC) endothelium and expand the SC lumen in a rat glaucoma model. In this study, we aimed to investigate the molecular mechanism of VIP on cytoskeleton regulation. METHODS: During in vivo experiments in rats, leucine-rich repeat kinase 2 (LRRK2) expression and the ratio of F-actin to G-actin (F-/G-actin) surrounding SC were examined by immunofluorescence after the application of VIP. For in vitro experiments in human umbilical vein endothelial cells, both quantitative PCR (qPCR) and western blotting were performed to evaluate Sp1 and LRRK2 expression after the application of VIP (and Sp1/LRRK2 inhibitor). In addition, the F-/G-actin ratio was examined by both immunofluorescence and western blotting after the application of VIP (and LRRK2 inhibitor). RESULTS: VIP induced increases in the expression of LRRK2 both in vivo and in vitro and the nuclear translocation of Sp1 in vitro. The application of Sp1 inhibitor abolished the increase in LRRK2 expression induced by VIP in vitro. In addition, VIP changed the F-/G-actin ratio, and this effect was abolished by the LRRK2 inhibitor both in vivo and in vitro. CONCLUSIONS: VIP increased the expression of LRRK2, and this regulation was due to the nuclear translocation of Sp1. VIP further changed the F-/G-actin ratio and regulated the balance between the stabilization and destabilization of the F-actin architecture. This study elucidates a novel mechanism by which VIP regulates the actin cytoskeleton of SC endothelium via the Sp1-LRRK2 pathway, suggesting a potential novel treatment strategy for glaucoma.
引用
- Yan X, Li M, Luo Z, et al. VIP Induces Changes in the F-/G-Actin Ratio of Schlemm's Canal Endothelium via LRRK2 Transcriptional Regulation. Invest Ophthalmol Vis Sci. 2020. PMID: 32572455. doi:10.1167/iovs.61.6.45
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。